Jordi Bruix

Q: What Schools Are Affiliated With Jordi Bruix

Jordi Bruix is affiliated with the following schools: University of California, Berkeley, Kyungpook National University, Stanford University, University of Glasgow, University of Barcelona

Jordi Bruix's AcademicInfluence.com Rankings

Jordi Bruix

Chemistry

#1074

World Rank

#1709

Historical Rank

Physical Chemistry

#84

World Rank

#104

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Jordi Bruix's Degrees

Bachelors Chemistry University of Barcelona
PhD Chemistry University of Barcelona

Why Is Jordi Bruix Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jordi Bruix's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Management of hepatocellular carcinoma: An update (2011) (7880)
Sorafenib in advanced hepatocellular carcinoma. (2008) (5771)
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. (2001) (3999)
Management of hepatocellular carcinoma (2005) (3633)
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) (3188)
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial (2002) (3117)
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival (2003) (2844)
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) (2654)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) (2452)
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. (2009) (1584)
Hepatocellular carcinoma (2012) (1367)
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. (2016) (1270)
Design and endpoints of clinical trials in hepatocellular carcinoma. (2008) (1216)
Hepatocellular carcinoma: clinical frontiers and perspectives (2014) (1187)
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. (2008) (1158)
Hepatocellular carcinoma (2003) (1120)
Prognostic prediction and treatment strategy in hepatocellular carcinoma (2002) (1103)
Current strategy for staging and treatment: the BCLC update and future prospects. (2010) (1010)
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma (2007) (952)
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. (2007) (885)
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. (2016) (878)
Molecular targeted therapies in hepatocellular carcinoma (2008) (852)
Novel advancements in the management of hepatocellular carcinoma in 2008. (2008) (848)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management (2020) (790)
Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma (2001) (725)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. (2012) (707)
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. (2015) (697)
The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma (2004) (687)
Pivotal role of mTOR signaling in hepatocellular carcinoma. (2008) (675)
Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma (2007) (645)
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. (2008) (566)
Management of HCC. (2012) (546)
Focus on hepatocellular carcinoma. (2004) (545)
Angiogenesis in liver disease. (2009) (523)
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. (2013) (522)
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma (2012) (511)
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. (2016) (500)
BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update (2021) (499)
Treatment of hepatocellular carcinoma. (2006) (486)
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. (2015) (481)
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma (2004) (430)
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma (2009) (425)
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. (2013) (418)
MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation (2003) (416)
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. (2012) (414)
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. (2017) (413)
LI‐RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the LI‐RADS Management Working Group and future directions (2015) (388)
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. (2006) (381)
A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma (2010) (378)
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. (2011) (378)
Hepatocellular carcinoma (2018) (372)
Hepatocellular carcinoma (HCC): a global perspective. (2010) (325)
New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. (2013) (325)
Chemoembolization for hepatocellular carcinoma. (2004) (325)
Hepatitis B virus and hepatocellular carcinoma. (2003) (303)
Major achievements in hepatocellular carcinoma (2009) (293)
Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast‐enhanced ultrasound (2010) (291)
High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation (2004) (280)
Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma (2009) (275)
Special article Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference (2001) (268)
Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation (2002) (265)
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches (2017) (259)
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. (2009) (258)
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. (2018) (252)
Treatment of intermediate-stage hepatocellular carcinoma (2014) (250)
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. (2018) (249)
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * (2011) (245)
Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta‐analysis (2015) (242)
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. (2010) (228)
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. (2009) (227)
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. (2011) (223)
Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment (2016) (217)
Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. (2018) (216)
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. (2013) (215)
Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second‐line trial design (2013) (214)
Liver cancer: Approaching a personalized care. (2015) (210)
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. (2014) (198)
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma (2010) (184)
World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. (2010) (182)
Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. (2012) (168)
Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. (2012) (162)
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial (2018) (160)
Screening for hepatocellular carcinoma: The rationale for the American Association for the Study of Liver Diseases recommendations (2012) (160)
Living donor liver transplantation for early hepatocellular carcinoma: A life‐expectancy and cost‐effectiveness perspective (2001) (155)
Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. (2003) (153)
Frequent inactivation of the tumor suppressor Kruppel‐like factor 6 (KLF6) in hepatocellular carcinoma (2004) (152)
Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma (2012) (147)
Hepatitis C virus and liver disease: Global transcriptional profiling and identification of potential markers (2003) (146)
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. (2019) (144)
Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib (2012) (143)
Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. (2012) (135)
Prognosis of hepatocellular carcinoma. (2002) (133)
“Very Early” Intrahepatic Cholangiocarcinoma in Cirrhotic Patients: Should Liver Transplantation Be Reconsidered in These Patients? (2014) (131)
Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Patients Undergoing Liver Transplantation: A Spanish Matched Cohort Multicenter Study (2014) (130)
Systemic treatment of hepatocellular carcinoma. An EASL position paper. (2021) (128)
Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution (2016) (128)
Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. (2015) (126)
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study (2021) (122)
Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. (2001) (121)
Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques (2011) (115)
Gene-expression signature of vascular invasion in hepatocellular carcinoma. (2011) (115)
Insights into the success and failure of systemic therapy for hepatocellular carcinoma (2019) (115)
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. (2012) (115)
Reply to: "Correspondence on the <BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update>". (2022) (113)
Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma (2017) (109)
Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma? (2006) (107)
Chemoembolization for intermediate HCC: is there proof of survival benefit? (2012) (107)
Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST (2014) (106)
Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence‐based decision (2003) (106)
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. (2012) (103)
Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. (2009) (102)
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. (2011) (102)
Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection (2016) (98)
Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. (2020) (95)
Prognostic prediction in patients with hepatocellular carcinoma. (2005) (92)
1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY (2012) (92)
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. (2007) (86)
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). (2020) (81)
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis (2013) (73)
Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure? (2017) (73)
Medical treatment for cholangiocarcinoma (2019) (72)
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. (2013) (70)
Treatment of hepatocellular carcinoma: is there an optimal strategy? (2003) (66)
Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer (2014) (65)
Diagnóstico y tratamiento del carcinoma hepatocelular (2009) (64)
A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group. (2015) (63)
Treatment of Hepatocellular Carcinoma (2016) (60)
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation (2019) (60)
Biomarkers for early diagnosis of hepatocellular carcinoma. (2012) (59)
STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC) (2014) (58)
Toward a Better Liver Graft Allocation That Accounts for Candidates With and Without Hepatocellular Carcinoma (2014) (58)
Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events (2018) (56)
Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study. (2004) (56)
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. (2019) (56)
Incidence of Hepatocellular Carcinoma in Patients with Non-alcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. (2021) (55)
HCC surveillance: Who is the target population? (2003) (53)
High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV‐1b–related cirrhosis (2001) (53)
Local and Regional Therapies for Hepatocellular Carcinoma (2020) (51)
Akt‐mediated foxo1 inhibition is required for liver regeneration (2016) (51)
LBA-03Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial (2016) (49)
Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography (2004) (48)
Selection of candidates with HCC for transplantation in the MELD era (2004) (48)
Screening for Liver Cancer: The Rush to Judgment (2012) (48)
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib (2018) (46)
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis (2021) (46)
Evolving role of regorafenib for the treatment of advanced cancers. (2020) (44)
Tratamiento del carcinoma hepatocelular en España. Análisis de 705 casos en 62 centros (2010) (44)
Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma (2018) (43)
Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria) (2018) (42)
[Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. (2016) (40)
Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial. (2017) (40)
49 PEGINTRON MAINTENANCE THERAPY IN CIRRHOTIC (METAVIR F4) HCV PATIENTS, WHO FAILED TO RESPOND TO INTERFERON/RIBAVIRN (IR) THERAPY: FINAL RESULTS OF THE EPIC3 CIRRHOSIS MAINTENANCE TRIAL (2009) (39)
Controversies in the management of hepatocellular carcinoma (2019) (39)
Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm. (2015) (39)
Systematic review with meta‐analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib (2019) (38)
Antiangiogenic therapy: Not just for cancer anymore? (2009) (37)
Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience. (2015) (36)
p27Kip1 is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma (2003) (36)
Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. (2009) (35)
Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). (2010) (35)
Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis (2006) (34)
Natural history and prognostic prediction of patients with hepatocellular carcinoma (2003) (34)
Biopsy for liver cancer: How to balance research needs with evidence‐based clinical practice (2015) (34)
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers]. (2010) (33)
Treatment of early hepatocellular carcinoma: Towards personalized therapy. (2010) (33)
Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. (2006) (32)
Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization. (2004) (32)
Prognostic assessment and evaluation of the benefits of treatment. (2002) (32)
The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma (2017) (31)
Systemic treatment. (2014) (31)
Contrast‐enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation (2003) (31)
Hepatocellular carcinoma: is surveillance cost effective? (2001) (31)
Multifaceted perspective of the waiting list for liver transplantation: The value of pharmacokinetic models (2010) (30)
Saudi Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Technical Review and Practice Guidelines (2012) (30)
Diagnosis of Small HCC. (2005) (30)
Value of transient elastography measured with fibroscan in predicting the outcome of hepatic resection for hepatocellular carcinoma. (2015) (30)
A DNA methylation signature associated with the epigenetic repression of glycine N-methyltransferase in human hepatocellular carcinoma (2013) (29)
Assessing the impact of COVID-19 on liver cancer management (CERO-19) (2021) (28)
Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery (2015) (28)
Applicability of adult-to-adult living donor liver transplantation. (2005) (27)
Hepatocellular carcinoma in the setting of liver transplantation (2006) (25)
Treatment strategies for hepatocellular carcinoma in cirrhosis (2003) (25)
Identification of coding and long non-coding RNAs differentially expressed in tumors and preferentially expressed in healthy tissues. (2019) (25)
Orthotopic Implantation of Human Hepatocellular Carcinoma in Mice (2004) (25)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial (2008) (25)
Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial (2017) (24)
New drugs for the treatment of hepatocellular carcinoma (2009) (24)
Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. (2017) (24)
A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. (2001) (24)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial (2008) (24)
Clinical Management of Hepatic Malignancies: Ferucarbotran-Enhanced Magnetic Resonance Imaging Versus Contrast-Enhanced Spiral Computed Tomography (2005) (23)
Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through Smad-independent TGF-β pathway (2016) (23)
For the EASL Panel of Experts on hepatocellular carcinoma (2001) (23)
Hepatocellular carcinoma – Authors' reply (2012) (23)
Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma (2020) (23)
Two decades of advances in hepatocellular carcinoma research. (2010) (22)
Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, SEOM, SERAM, SERVEI y SETH ☆ (2016) (22)
Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. (2020) (22)
67 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): SUBANALYSIS OF SHARP TRIAL BASED ON BARCELONA CLINIC LIVER CANCER (BCLC) STAGE (2009) (21)
Selective Inhibition of Hepatitis C Virus Infection by Hydroxyzine and Benztropine (2014) (21)
Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study (2018) (21)
Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care (2007) (21)
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program. (2011) (21)
Surgical resection for hepatocellular carcinoma: Moving from what can be done to what is worth doing (2015) (21)
Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). (2011) (20)
Treatment of Hepatocellular Carcinoma (2014) (20)
Ablation for hepatocellular carcinoma: Is there need to have a winning technique? (2010) (19)
Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma (2019) (19)
Exposure–response relationship of regorafenib efficacy in patients with hepatocellular carcinoma (2017) (18)
Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma (2010) (18)
p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. (2003) (18)
End-points in clinical trials for liver cancer and their value in evidence based clinical decision making: an unresolved Gordian knot. (2021) (17)
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. (2014) (17)
Transarterial chemoembolization for patients with hepatocellular carcinoma (2007) (17)
6576 POSTER Phase II Safety Study of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as Second-line Therapy in Patients With Hepatocellular Carcinoma (2011) (16)
East meets the West—portal pressure predicts outcome of surgical resection for hepatocellular carcinoma (2009) (16)
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials (2021) (16)
Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. (2020) (15)
Efficacy and safety of sorafenib in patients with alcohol-related hepatocellular carcinoma: A sub-analysis from the SHARP trial (2008) (15)
Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium (2016) (14)
Liver transplantation in hepatocellular carcinoma (2005) (14)
Prognostic prediction in HCC: Did anybody expect it to be easy? (2004) (14)
Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis (2019) (14)
Tumour recurrence after Interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumour growth (2017) (14)
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET—Letter (2013) (14)
Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo (2017) (13)
Hepatic epithelioid hemangioendothelioma: An international multicenter study. (2020) (13)
Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HCC) (2001) (13)
Lenvatinib: can a non-inferiority trial change clinical practice? (2018) (13)
Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. (2003) (13)
Treating hepatitis C in patients with cirrhosis: the effort is worth it. (2010) (13)
994 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND PRIOR ANTI-TUMOR THERAPY: A SUBANALYSIS FROM THE SHARP TRIAL (2008) (12)
Liver cancer: Still a long way to go (2011) (12)
International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis (2020) (12)
Diagnosis of Hepatic Nodules in Patients at Risk for Hepatocellular Carcinoma: LI-RADS Probability Versus Certainty. (2019) (12)
Weak correlation of overall survival and time to progression in advanced hepatocellular carcinoma. (2017) (12)
Hepatocellular carcinoma: current state of the art in diagnosis and treatment. (2014) (12)
Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial (2019) (12)
Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis. (2017) (12)
Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC). (2013) (12)
Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study (2021) (11)
1250 Predictors of drop-out and survival of patients with hepatocellular carcinoma candidates for liver transplantation (2003) (11)
Effect of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ECOG performance status (ECOG PS) on outcome in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib: Analysis of two phase III, randomized, double-blind trials. (2009) (11)
1057 PLASMA BIOMARKERS AS PREDICTORS OF OUTCOME IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: RESULTS FROM THE RANDOMIZED PHASE III SHARP TRIAL (2009) (11)
Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial (2016) (10)
Abstract No LB12: A prospective, multicenter phase II clinical trial using irreversible electroporation for the treatment of early stage HCC (2012) (10)
Pattern of tumor progression in liver cancer: The missing partner in trial design (2015) (10)
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma (2017) (10)
Comparison of modified (m)RECISTand RECIST 1.1 assessments in the phase 3 RESORCE trial comparing regorafenib and placebo in patients with hepatocellular carcinoma who progressed during sorafenib treatment (2017) (10)
Sunitinib and the benefits of a negative study. (2009) (10)
Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment. (2017) (9)
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study. (2013) (9)
Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma. (2011) (9)
Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients. (2006) (9)
Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. Estudio de 686 casos en 73 centros (2017) (9)
Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. (2021) (9)
Carcinoma hepatocelular. Indicación y manejo en lista de espera (2004) (9)
Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models (2020) (9)
Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma (2017) (8)
Limited tumor progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. (2021) (8)
Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. (2017) (8)
Abstract 3183: Initial safety of AFP SPEAR T-cells in patients with advanced hepatocellular carcinoma (2019) (8)
Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC). (2016) (7)
Efficacy and safety of sorafenib (Sor) in patients (Pts) with advanced hepatocellular carcinoma (HCC): Subgroup analyses of the SHARP trial by baseline (BL) transaminase (ALT/AST)/α-fetoprotein (AFP) and bilirubin (bil) levels. (2010) (7)
Diagnóstico temprano del cáncer de hígado (2005) (7)
Pseudotumoral hepatic tuberculosis. (2003) (7)
Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing". (2016) (7)
Restoring MIR122 in Human Stem-Like Hepatocarcinoma Cells, Prompts Tumor Dormancy through Smad-Independent TGF-B Pathway (2016) (7)
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors (2022) (7)
[Usefulness of the molecular profile in the diagnosis, prognosis and treatment of hepatocellular carcinoma]. (2014) (6)
If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection? (2013) (6)
Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid (2020) (6)
Portal pressure in patients with exudative ascites in the course of acute hepatitis B. (2008) (6)
Outcome of liver cancer patients with SARS‐CoV‐2 infection: An International, Multicentre, Cohort Study (2022) (6)
Abstract LB-233: IGF activation in a molecular subclass of hepatocellular carcinoma and preclinical efficacy of IGF-1R blockage (2010) (6)
The Size of the Problem: Clinical Algorithms (2013) (6)
Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial (2017) (6)
Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity (2021) (6)
295 Final Results of the EPIC3 Cirrhosis Maintenance Trial: Pegintron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV Patients, Who Failed to Respond to Interferon/Ribavirn (IR) Therapy: (2009) (6)
Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma. (2020) (6)
Ecografía con contraste en el diagnóstico del carcinoma hepatocelular (2013) (5)
O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma (2020) (5)
Prognostic factors and predictors of sorafenib beneﬁt in patients with hepatocellular carcinoma: Analysis of two phase III studies (2017) (5)
Expected developments in hepatology. (2002) (5)
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules (2021) (5)
Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients (2021) (5)
Diagnosis and staging of hepatocellular carcinoma prior to transplantation: Expertise or failure (2006) (5)
Management of Hepatocellular Cancer (2007) (5)
Sorafenib for hepatocellular carcinoma: global validation. (2009) (5)
[Diagnosis and treatment of hepatocellular carcinoma]. (2009) (5)
Chapter 80 – Hepatocellular carcinoma (2012) (5)
The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments (2017) (5)
Utilidad del perfil molecular en el diagnóstico, pronóstico y tratamiento del carcinoma hepatocelular (2014) (5)
RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR). (2014) (5)
Corrigendum to "Diagnosis and staging of hepatocellular carcinoma (HCC): Current guidelines" [Eur. J. Radiol. 101 (2018) 72-81]. (2019) (5)
Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti‐VEGF/TKI and immunotherapy (2022) (5)
Corrigendum to "Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies" [J hepatol 67 (2017) 999-1008]. (2018) (4)
Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH (2021) (4)
Towards personalized screening for hepatocellular carcinoma: still not there. (2020) (4)
Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types (2021) (4)
1408 IRREVERSIBLE ELECTROPORATION FOR THE TREATMENT OF EARLY-STAGE HEPATOCELLULAR CARCINOMA. A PROSPECTIVE MULTICENTER PHASE 2 STUDY ASSESSING SAFETY AND EFFICACY (2012) (4)
Consideraciones acerca de la Conferencia de Barcelona sobre diagnóstico y tratamiento del carcinoma hepatocelular (2002) (4)
Liver cancer: An evolving challenge reaching research maturity (2008) (4)
Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients. (2016) (4)
Towards personalised approach in systemic treatment for hepatocellular carcinoma. The value of AGT M235T gene polymorphism (2018) (4)
Locoregional versus systemic therapy — robust positive data remain elusive (2018) (3)
Regorafenib as second-line treatment for patients with HCC who progressed on sorafenib: Japanese subgroup analysis of phase 3 RESORCE trial (2017) (3)
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials (2020) (3)
Hepatocellular Carcinoma: Paving the Road for Further Developments (2014) (3)
SAT-482-Incidence of hepatocellular carcinoma after hepatitis C cure with DAA in a cohort of patients with advanced liver disease: Results from a prospective screening program (2019) (3)
BIOMARKER RESULTS FROM ARQ 197-114: A PHASE 1B TRIAL EVALUATING THE c-MET INHIBITOR ARQ 197 IN CIRRHOTIC PATIENTS (PTS) WITH HEPATOCELLULAR CARCINOMA (HCC) (2010) (3)
Diagnosis of early hepatocellular carcinoma: ideal goal, but not yet there. (2011) (3)
FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive? (2014) (3)
Population pharmacokinetics (popPK) to evaluate the effect of intrinsic and extrinsic factors on regorafenib (REG) exposure in REG studies including patients with hepatocellular carcinoma (HCC). (2017) (3)
Radiological endpoints as surrogates for survival benefit in Hepatocellular Carcinoma trials: all that glitters is not gold. (2022) (3)
Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells (2020) (3)
To expand or not to expand the criteria for hepatocellular carcinoma transplantation: is downstaging the answer? (2009) (3)
625PDProtein biomarkers as predictors of outcome with regorafenib (REG) in patients (pts) with hepatocellular carcinoma (HCC) in the RESORCE trial (2017) (2)
Intermediate-stage HCC—upfront resection can be feasible (2015) (2)
Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial. (2013) (2)
24 A NOVEL MOLECULAR CLASSIFICATION OF HCV-RELATED HEPATOCELLULAR CARCINOMA (HCC) BASED ON INTEGRATIVE GENOMIC ANALYSIS (2008) (2)
705PCirculating miRNA biomarkers predicting regorafenib (REG) clinical benefit in patients with hepatocellular carcinoma (HCC) in the RESORCE trial (2017) (2)
[Treatment of advanced hepatocellular carcinoma]. (2010) (2)
645 SERUM CARBONIC ANHYDRASE 9 (CA) IS A VALUABLE BIOMARKER (BM) TO PROFILE PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH SORAFENIB AND PREDICT THEIR OUTCOME (2011) (2)
6519 Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): collective results from the phase III sorafenib HCC assessment randomized protocol (SHARP) and Asia-Pacific (AP) trials (2009) (2)
Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. (2020) (2)
Optimization of Survival Prediction in Patients under Sorafenib Treatment: Usefulness of Carbonic Anhydrase IX Baseline and Baseline and Evolutive Angiopoyetin 2 (2016) (2)
El trasplante hepático en adulto de donante vivo hoy (2004) (2)
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma (2021) (2)
Failure of interferon to prevent disease progression and liver cancer in hepatitis C virus infection: proof of absence or absence of proof? (2010) (2)
Intention-to-treat curative liver resection in patients with “very early” intrahepatic cholangiocarcinoma (2020) (2)
Detección precoz del carcinoma hepatocelular en pacientes cirróticos (2006) (2)
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis (2023) (2)
226 EFFICACY AND SAFETY OF SORAFENIB AT LONG TERM IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): NEED TO SCREEN FOR CARDIOVASCULAR EVENTS AFTER LONG TERM ADMINISTRATION (2010) (2)
Treatment of hepatocellular carcinoma with radioembolization: gathering assumptions for trial design. (2013) (2)
Overall Survival (OS) Update: 2-year follow-up from the phase-3 RESORCE trial of Regorafenib for patients with hepatocellular carcinoma (HCC) progressing on Sorafenib (2019) (2)
Authors’ response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong et al (2014) (2)
Hepatic Surgeons Are Like the Child Who Rescued Dying Fish REPLY (2016) (2)
Tratamiento del carcinoma hepatocelular avanzado (2010) (2)
The “six-and-twelve” score in a prospective cohort of patients with hepatocellular carcinoma treated with trans-arterial chemoembolization following a fixed schedule (2020) (2)
Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication. (2017) (2)
Hepatocarcinoma y VHC (2006) (2)
PS-115-Evaluation of LI-RADS v2018 by magnetic resonance in US-detected nodules < 2 cm in cirrhotics (2019) (2)
267 DERMATOLOGIC ADVERSE EVENTS WITHIN THE FIRST 60 DAYS OF SORAFENIB TREATMENT ARE ASSOCIATED WITH BETTER OVERALL SURVIVAL (OS) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) (2013) (2)
Abstract 2996: Overexpression of potential oncogenic microRNAs defines a new molecular subclass of hepatocellular carcinoma (2010) (2)
The challenges of novel contrast agents for the imaging diagnosis of hepatocellular carcinoma (2013) (2)
Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections. (2021) (2)
Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, AEC, SEOM, SERAM, SERVEI y SETH (2021) (2)
POLYETHYLENE-GLYCOL DRUG-ELUTING EMBOLIC MICROSPHERES LOADED WITH DOXORUBICIN FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: FEASIBILITY, SAFETY AND PHARMACOKINETIC STUDY. (2022) (2)
The need for novel and interesting data in liver cancer research (2009) (2)
Breakthroughs in hepatocellular carcinoma therapies. (2023) (1)
Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity (2021) (1)
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib (2022) (1)
The search for an effective partner for sorafenib: the failure of doxorubicin. (2011) (1)
miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma (2022) (1)
Impact of lymph node metastases on outcome following treatment with sorafenib in patients with hepatocellular carcinoma (HCC): Subset analysis from the phase III SHARP trial. (2016) (1)
Regorafenib improves survival after sorafenib in patients with recurrent HCC after liver transplantation (2021) (1)
Tumors of the Liver (2012) (1)
Reply: Chemoembolization with drug eluting beads in HCC (2007) (1)
1016 DIAGNOSIS OF HEPATOCELLULAR CARCINOMA (HCC) ≤2 CM: PROSPECTIVE VALIDATION OF GLYPICAN 3, HEAT-SHOCK PROTEIN 70 AND GLUTAMINE SYNTHETASE S TAINING IN BIOPSY SAMPLES (2011) (1)
36. Hepatocellular Carcinoma (2011) (1)
Medical treatments: in association or alone, their roles and their future perspectives (2010) (1)
Abstract CT207: Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors (2021) (1)
815 SORAFENIB FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA. FEASIBILITY AND SAFETY OUTSIDE RESEARCH TRIALS (2009) (1)
596TiP Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours (2020) (1)
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial (2022) (1)
2 DISRUPTION OF IGF SIGNALING IN EARLY HEPATOCELLULAR CARCINOMA AND PRE-CLINICAL EFFICACY OF ANTI-IGF1R BLOCKING THERAPIES (2008) (1)
Safety, tolerability and efficacy of transarterial chemoembolization using anthracyclines-loaded drug eluting microspheres for treatment of patients with unresectable hepatocellular carcinoma: Pooled analyses. (2021) (1)
269 INTRAHEPATIC CHOLANGIOCARCINOMA (I-Cc) OR MIXED HEPATOCELLULAR–CHOLANGIOCARCINOMA (HCC-CC) IN PATIENTS UNDERGOING LIVER TRANSPLANTATION. A SPANISH CASE CONTROL MULTICENTER STUDY (2013) (1)
Liver Metastases From Gastric Adenocarcinoma Mimicking Multinodular Hepatocellular Carcinoma (2018) (1)
Reply to: "Response to Mariño et al. J Hep 2019 Study: The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut". (2019) (1)
Early diarrhoea under sorafenib as a marker to consider the early migration to second‐line drugs (2021) (1)
CeO2NPs are similarly effective as sorafenib in increasing survival in rats with HCC (2018) (1)
P0260 : Liver kinase B1 as an oncogenic driver in liver cancer (2015) (1)
Percutaneous treatment for unresectable hepatocellular carcinoma. Predictors of long-term survival of 274 patients in a single institution (2003) (1)
2014 IMPROVED INFLAMMATORY ACTIVITY WITH LOW-DOSE PEGINTRON (PEG) MAINTENANCE THERAPY IN PRIOR NONRESPONDERS WITH METAVIR FIBROSIS SCORES (MFS) OF F2/F3: FINAL RESULTS FROM THE EPIC3 PROGRAM (2010) (1)
Safety and effectiveness of Regorafenib in recurrent HCC after liver transplantation and progression on Sorafenib: a real-life multicentre study (2019) (1)
Liver Imaging Reporting and Data System: Review of Pros and Cons (2021) (1)
273 Usefulness of sonovue microbubble-enhanced ultrasonography in the assessment of the efficacy of percutaneous ablation in patients with hepatocellular carcinoma (2004) (1)
Exposure-response (ER) relationship of regorafenib (REG) in patients with hepatocellular carcinoma (HCC). (2017) (1)
215 A PHASE II OPEN LABEL TRIAL EVALUATING SAFETY AND EFFICACY OF A TELOMERASE PEPTIDE VACCINATION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (2010) (1)
[Considerations of the Barcelona Conference on the diagnosis and treatment of hepatocellular carcinoma]. (2002) (1)
Early Nivolumab addition to Regorafenib in patients with hepatocellular carcinoma progressing under 1st line therapy (GOING trial). Interim analysis and safety profile (2022) (1)
Sorafenib/Regorafenib resistance and BH3-mimetics efficacy in hepatocellular carcinoma treatment is determined by mitochondrial changes in the BCL-2 profile (2018) (1)
The pituitary tumour‐transforming gene 1/delta‐like homologue 1 pathway plays a key role in liver fibrogenesis (2022) (1)
Reply (2016) (1)
702PCorrelation between overall survival (OS) and time to progression (TTP) and between OS and response rate (RR) by RECIST in advanced hepatocellular carcinoma (HCC) (2017) (1)
Updated data from an ongoing study with ADP-A2AFP spear T-cells (2020) (1)
Prospective evaluation of gadoxetic-acid MR for the non-invasive diagnosis of hepatocellular carcinoma in newly detected nodules <=2 cm in cirrhotic patients (2018) (1)
Impact of regorafenib in the clinical practice and identification of second-line treatment orphan patients (2018) (1)
669 MYC IS ESSENTIAL FOR KEEPING CANCER STEM CELL (CSC)-LIKE PHENOTYPE IN HUMAN HEPATOCELLULAR CARCINOMA (HCC) (2011) (1)
Systemic Treatment: Expecting Further Success (2015) (1)
Transarterial Chemoembolization with Anthracyclines-Loaded Polyethylene Glycol Drug Eluting Microspheres for the Treatment of Hepatocellular Carcinoma: A Pooled Multicentric Analysis of Survival in 580 Patients (2023) (1)
MicroRNA analysis for outcome prediction in hepatitis B virus-related liver cancer. (2010) (1)
Analysis of tumor growth rate for advanced hepatocellular cancer patients receiving placebo or sorafenib in the phase 3 SHARP and Asia Pacific trials (2016) (1)
Analysis of single-nucleotide polymorphisms (SNPs) in the phase III RESORCE trial of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC). (2018) (1)
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors (2022) (1)
227 CHANGES IN TUMOR BLOOD VOLUME AND PERFUSION ASSESSED PERFUSION COMPUTED TOMOGRAPHY PREDICT THE TIMING OF TUMOR PROGRESSION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB (2010) (1)
Chapter 91 – Hepatocellular carcinoma (2017) (1)
Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success (2018) (1)
La ecografia con contraste de segunda generacion (SonoVue) en la valoracion del tratamiento percutáneo del carcinoma hepatocelular. Comparación con la TC multifásica (2005) (1)
TCF1/HNF1 mutations in hepatocellular adenoma (2003) (0)
Corrigendum to: “FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program” [J Hepatol 2011;54:227–235] (2013) (0)
MIR-873 Promotes Liver De-Differentiation and Fibrosis Targeting Glycine-N-Methyl Transferase (2016) (0)
P0390 : Baseline bilirubin and not Child-Pugh a or B7 predicts survival of BCLC B patients treated with sorafenib. The clinical approach to the stratification debate (2015) (0)
Complete Response under Sorafenib Treatment for Hepatocellular Carcinoma is Associated to Development of Dermatology Adverse Events (2016) (0)
133 DYSREGULATION OF FIBROBLAST GROWTH FACTOR NETWORK IN EARLY HEPATOCELLULAR CARCINOMA (2011) (0)
Abstract #444: Molecular and clinical characterization of RICTOR (MTORC2) as a candidate oncogene in hepatocellular carcinoma (2009) (0)
“Very early” intrahepatic cholangiocarcinoma may become an acceptable indication for liver transplantation. A multicenter validation study (2016) (0)
PROBLEMAS DURANTE EL PERÍODO PERIOPERATORIO DEL TRASPLANTE HEPÁTICO: PROFILAXIS Y TRATAMIENTO (2016) (0)
Lkb1 Activates Ras Pathway in Hepatocellular Carcinoma by Transcriptional and Post-Translational Regulation of Rasgrp3 (2016) (0)
Efectividad y eficacia del tratamiento percutáneo de los (2001) (0)
liver imaging r eporting and Data s ystem with M r imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at (2015) (0)
Reply (2005) (0)
FRI-473-Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: A real-life multicentre study (2019) (0)
O94 NEDDYLATION CONTROLS LIVER TUMOURS SURVIVAL STABILIZING Akt AND LKB1 AND REPROGRAMMING CANCER METABOLISM (2014) (0)
Empowerment of liver cancer patients for an improved management of post-embolization syndrome: impact of a nurses educational program (2020) (0)
967 ATYPICAL PATTERNS OF HCC ON MRI. ANALYSIS OF FAT, CAPSULE AND SIGNAL INTENSITY (2011) (0)
647 LIVER TRANSPLANTATION FOR INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) AND COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA(CHCC-CC) (2011) (0)
Reply: (2008) (0)
Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment (2022) (0)
FRI-461-Thermal ablation is a safe and effective treatment for intrahepatic cholangiocarcinoma in patients with cirrhosis (2019) (0)
Ablative therapy for hepatocellular carcinoma: Evidence to support an aggressive initial treatment strategy (2005) (0)
Hepatocellular Carcinoma in the EU (2012) (0)
Transarterial Embolization for Patients with Hepatocellular Carcinoma (2009) (0)
SAT-483-Hepatic epithelioid hemangioendotelioma: An international multicenter study (2019) (0)
Reply (2017) (0)
1026 PROGRESSION RATE PROFILE AND RELATIONSHIP WITH SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB BEYOND FIRST PROGRESSION (2012) (0)
266 Evidence of hedgehog signaling pathway activation in hepatocellular carcinoma (2006) (0)
743 APPLICABILITY OF CURATIVE TREATMENTS IN PATIENTS WITH VERY EARLY HEPATOCELLULAR CARCINOMA (BCLC-0). A GROWING NEED IF FOLLOWING PRACTICE GUIDELINES (2012) (0)
790 INTRAHEPATIC CHOLANGIOCARCINOMA IN CIRRHOTIC LIVER; ROLE OF DELAYED PHASES (2009) (0)
FRI-417-Impact of a nurse educational program and accessibility in the management of patients with hepatocellular carcinoma under systemic treatment (2019) (0)
Regorafenib improves survival after sorafenib treatment in patients with recurrent hepatocellular carcinoma after liver transplantation, compared to best supportive care (2020) (0)
Cerium oxide nanoparticles display anti-tumoral activity and improve survival in experimental hepatocellular carcinoma (2017) (0)
Liver Transplantation for Hepatocellular Carcinoma in HCV-Infected Patients (2014) (0)
Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma: Evaluating community guideline adherence. (2010) (0)
Clinicopathological evaluation of skin lesions (SL) in patients with hepatocellular carcinoma (HCC) treated with sorafenib. (2018) (0)
Hepatic Oncology: a journal for all stakeholders in liver cancer management. (2014) (0)
Gene expression profiles of pre-neoplastic lesions and hepatocellular carcinoma in hepatitis C virus -cirrhotic patients (2005) (0)
Liver Transplantation for Tumors (2007) (0)
P0379 : Cancer related symptoms (performance status 0 vs 1) determine prognosis of hepatocellular carcinoma patients treated with sorafenib. Analysis of a prospective data collection in 207 patients (2015) (0)
FibroTest™ Is an Independent Predictor of Early and Sustained Virologic Response in Nonresponder Patients With Chronic Hepatitis C: Results From the EPIC 3 Study (2009) (0)
Reply (to LTE HEP-17-1030.R1) (2017) (0)
126 Complications in the donor after right-lobe adult living donor liver transplantation (LDLT) (2004) (0)
Iconography : Biomarkers for early diagnosis of hepatocellular carcinoma (2012) (0)
340 Sorafenib Treatment Inhibits Non-Parenchymal Cells After 2/3 Partial Hepatectomy in Mice, but Does Not Impair Liver Regeneration (2010) (0)
Letter: are sorafenib‐related adverse events associated with prolonged survival? Authors' reply (2020) (0)
[275] SEQUENCING OF HVRII AND HVRIII OF MITOCHONDRIAL DNA ALLOWS THE DISTINCTION BETWEEN DISSEMINATED AND SYNCHRONIC HEPATOCELLULAR CARCINOMA (HCC) (2007) (0)
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association (2022) (0)
Portal Hypertension may Influence the Registration of Hypointensity of Small Hepatocellular Carcinoma in the Hepatobiliary Phase in Gadoxetic Acid MR (2022) (0)
Interferon for the prevention of hepatocellular carcinoma (2002) (0)
SO-8 Safety, tolerability, and efficacy of transarterial chemoembolization using anthracyclines-loaded drug-eluting microspheres for treatment of patients with unresectable hepatocellular carcinoma: Pooled analyses (2020) (0)
Pancreatic insufficiency related to hepatocellular carcinoma treatment: early detection and treatment improves therapeutic adherence (2017) (0)
THU-444-Alteration of miRNAs expression in patients with HCV-related cirrhosis who developed HCC after therapy with DAAs (2019) (0)
Abstract 1387: The importance of FGF pathway in hepatocellular carcinoma and its role in acquired resistance to anti-angiogenic therapies (2012) (0)
Reply (2015) (0)
Systematic review and metanalysis establish dermatologic adverse events as a positive predictor of survival in hepatocellular carcinoma patients treated with sorafenib (2018) (0)
PS-137-A multicentric study on real-life impact of nivolumab in patients with hepatocellular carcinoma (2019) (0)
Chapter 59 – Hepatocellular Carcinoma (2006) (0)
Impact of a nurse educational program for patient empowerment during sequential systemic therapy for hepatocellular carcinoma (2020) (0)
Increased risk of liver cancer in cirrhotic patients associated to direct acting antivirals (2018) (0)
261 Exclusion of subcapsular tumors prevents peritoneal seeding in hepatocellular carcinoma (HCC) patients treated with radiofrequency (2004) (0)
Nelson Fausto (1936–2012) (2012) (0)
Reply (2001) (0)
Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma". (2017) (0)
State-ofthe-art Integration of Multikinase Inhibitors in the Treatment of Gastrointestinal Cancers (2016) (0)
Reply to: ''Poor contrast enhanced ultrasonography! There is no limit to its decline in the diagnosis of hepatocellular carcinoma on cirrhosis!''. (2015) (0)
Impact of PegIntron (PEG) Maintenance Therapy (MT) on Fibrosis Biomarkers (FibroTest (FT)/FibroSURE) in Prior Nonresponders With METAVIR Fibrosis Scores (MFS) of F2/F3: Final Results From the EPIC 3 Program (2010) (0)
Reply: To PMID 25212123. (2015) (0)
11. Hepatocellular Carcinoma (2012) (0)
Clinical Characteristics of Intrahepatic Cholangiocarcinoma in Spain. Liver Cirrhosis and High AFP are not Always Hepatocellular Carcinoma (2016) (0)
277 SKP2 overexpression is associated to reduced P27K1P1 protein levels in human hepatocellular carcinoma (2004) (0)
HCC-neuroendocrine transition: Tumor plasticity under immunotherapy (2022) (0)
Incidence of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: A meta-analysis and meta-regression (2021) (0)
FRI-462-A multicenter international study of sorafenib treatment in patients with hepatocellular carcinoma and chronic kidney disease undergoing hemodialysis (2019) (0)
Thank you to reviewers (2005) (0)
Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response". (2019) (0)
PrevenciÓn del desarrollo de carcinoma hepatocelular (2003) (0)
p27Kip1 Is an independent predictor of recurrence after surgical resection of hepatocellular carcinoma (HCC) (2001) (0)
VEGF and iNOS expression in human hepatocellular carcinoma (HCC) (2001) (0)
328 Tumor Acidosis Induces Cancer Stem Cell (Csc) Markers in Human Hepatocellular Carcinoma (Hcc) Cell Lines (2012) (0)
Transarterial-chemoembolization and hepatocellular carcinoma. A regular interval approach avoids the 10% of the procedures and an optimal survival with the transition to systemic therapy in 80% of the patients (2018) (0)
770 Safety, efficacy, and pharmacokinetic results from a phase I first-in-human study of ABBV-151 with or without anti-PD1 mAb (budigalimab) in patients with locally advanced or metastatic solid tumors (2022) (0)
PlasmaBiomarkersasPredictorsofOutcomeinPatientswith Advanced Hepatocellular Carcinoma (2012) (0)
Reply: (2017) (0)
Reply (2011) (0)
Inheriting a Jewel: A Thrilling Challenge (2016) (0)
814 EVALUATION OF TUMOR PERFUSION AT COMPUTED TOMOGRAPHY AS A TOOL TO DETECT THE EFFECT OF SORAFENIB TREATMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) (2009) (0)
EASL/AASLD Guidelines (2008) (0)
THU-442-Role of drug transporters in the chemoresistance of hepatoblastoma (2019) (0)
Reply: (2010) (0)
Angiogenesis in liver disease q (2009) (0)
1169 GENERATION OF PERMISSIVE BCLC5 CELL LINES FOR THE STUDY OF HCV REPLICATION: ROLE OF miR122 IN REPLICATION ENHANCEMENT (2013) (0)
122 GENOME-BASED MODELING PROGNOSIS IN HEPATOCELLULAR CARCINOMA: PROLIFERATION-G3 AND ADJACENT POOR SIGNATURES INDEPENDENTLY PREDICT RECURRENCE (2010) (0)
Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884]. (2020) (0)
Liver FoxO1 overexpression is positively associated with the degree of liver injury in cirrhotic patients (2020) (0)
In response to: Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation. (2016) (0)
A DNA methylation signature associated with the epigenetic repression of glycine N-methyltransferase in human hepatocellular carcinoma (2013) (0)
Reply: Noninvasive diagnostic criteria for hepatocellular carcinoma: A boat that leaks like a sieve (2010) (0)
Abstract 2361: Big data analysis allows the identification of long non-coding RNAs with therapeutic potential against hepatocellular carcinoma (2018) (0)
Orthotopic implantation of human hepatocellular carcinoma in mice. Establishment of the BCLC-9 cell line (2003) (0)
COMPLICATIONS IN THE RIGHT-LOBE ADULT LIVING DONOR LIVER TRANSPLANTATION (LDLT) (2004) (0)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma : Subanalyses of a phase III trial q , qq (2012) (0)
830 INFECTION AND REPLICATION OF HEPATITIS C VIRUS IN BCLC HUMAN HEPATOCELLULAR CARCINOMA CELL LINES (2012) (0)
704 ABSENCE OF ARTERIAL HYPERVASCULARIZATION AT CEUS DOES NOT RULE OUT HEPATOCELLULAR CARCINOMA IN NODULES ≤2 CM IN A CIRRHOTIC LIVER (2012) (0)
[Ophthalmology meeting in Palma de Mallorca, 1934]. (2006) (0)
280 ROLE OF cMYC IN CELL DORMANCY DISRUPTION IN LATENT TUMORS ESTABLISHED FROM HUMAN HEPATOCELLULAR CARCINOMA (HCC) CELL LINES (2013) (0)
The Accuracy of the Baseline Peripheral Lymphocyte Value in Predicting Overall Survival in Hepatocellular Carcinoma Patients Treated with Sorafenib Reinforces the Impact of the Immune Response on Tumor Progression (2016) (0)
P0391 : Prior history of arterial hypertension is not a contraindication to sorafenib and is associated to a better survival in patients with advanced HCC (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jordi Bruix?

Jordi Bruix is affiliated with the following schools:

University of California, Berkeley
Kyungpook National University
Stanford University
University of Glasgow
University of Barcelona